A142 INFLAMMATORY BOWEL DISEASE PATIENTS REQUIRE AN INCREASED ADALIMUMAB DRUG LEVEL TO SIMULTANEOUSLY ACHIEVE CLINICAL AND BIOLOGICAL REMISSION

BACKGROUND: Physicians use therapeutic drug monitoring of adalimumab (ADA) as an optimization tool to guide patient therapy with inflammatory bowel disease (IBD). IBD consists primarily of Crohn’s disease (CD) and ulcerative colitis (UC). Presently, the literature on ADA therapeutic boundaries recom...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Can Assoc Gastroenterol
Asıl Yazarlar: Cookson, T A, Stern, N C, Sutton, R T, Fedorak, R, Halloran, B, Dieleman, L A, Wong, K, Huang, V, Peerani, F, van Zanten, S, Lazarescu, A, Kroeker, K
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2019
Konular:
Posters Of Distinction
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512604/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz006.141
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller